Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 7Completed 5Unknown 4Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Breast Neoplasms 1296Carcinoma, Non-Small-Cell Lung 793Neoplasms 787Colorectal Neoplasms 760Stomach Neoplasms 587Carcinoma, Hepatocellular 581Prostatic Neoplasms 514Lung Neoplasms 466Pancreatic Neoplasms 421Rectal Neoplasms 336Recurrence 314Neoplasm Metastasis 308Leukemia, Myeloid, Acute 293Colonic Neoplasms 283Multiple Myeloma 280Lymphoma 276Esophageal Neoplasms 273Uterine Cervical Neoplasms 272Ovarian Neoplasms 263Melanoma 246Head and Neck Neoplasms 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 210Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 187Nasopharyngeal Carcinoma 182Leukemia 173Lymphoma, Non-Hodgkin 171Liver Neoplasms 165Glioblastoma 160Polycystic Ovary Syndrome 157

Interventions

tislelizumab 1Sirolimus 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Interventional × Malignant Solid Tumors × Clear all
NCT06082557 2023-10-13

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Unknown
62 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05508620 2022-08-23

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Unknown
270 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05441046 2022-07-06

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
120 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT01694472 2015-12-22

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
15 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡